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1. Introduction 
Human immunodeficiency virus (HIV), a retrovirus that was clinically detected in 1980 and 
demonstrated to be the causative agent of acquired immunodeficiency syndrome (AIDS), 
had resulted in over 25 million deaths by 2005. Currently, more than 33 million people are 
HIV-positive, and approximately 2.6 million people were newly infected and 1.8 million 
died of AIDS-related disorders in 2009. Antiretroviral therapy (ART), available from the 
mid-1990s, greatly improves the quality of life for HIV-infected persons and reduces 
mortality. However, there are several limitations to obtaining recovery from HIV infection 
including drug resistance, high rate of viral mutations, limited number of targets, low 
bioavailability of some compounds, presence of viral reservoirs and severe side-effects. The 
inability of standard highly active anti-retroviral therapy (HAART) drugs to penetrate some 
cells ensures that virus replication continues, although the common viral load can be 
reduced to undetectable levels [Finzi, 1997]. In addition, owing to the high cost and 
complexity of current HIV therapies, fewer than 5% of HIV infected patients worldwide 
receive antiretroviral treatment, and in underdeveloped countries access to such drugs is 
severely restricted. Therefore, development of preventive and therapeutic vaccines represents 
a tremendous challenge to AIDS researchers. In Europe the elaboration of new therapies is one 
of the main goals and  several studies have concerned nanotechnology, with gene therapy 
being proposed as a good alternative that can efficiently inhibit gene expression in a sequence-
specific manner. Dendrimers, a new class of polymeric molecules, are potential candidates for 
developing preventive antiretroviral vaccines where the delivery vehicles have low level 
cytotoxicity and targeted action. The aim of this chapter is to summarize studies concerning 
dendrimers and their application as therapy against HIV-1. 
2. HIV-1 pandemic. Fail of HAART. The necessity of a new therapy approach 
Conventional antiretroviral therapy consists of a combination of antiviral drugs to decrease 
the mortality of HIV-1 infected patients [Palella et al., 1998], with the mixture of drugs 
interfering with various stages of the virus life cycle at one time. Therefore, antiretroviral 
therapies (ART) are targeted to block key steps of the viral replication cycle: binding and 
fusing to the target host CD4 T-cell, reverse transcription of the viral RNA, and integration 
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of viral DNA into host DNA. For a better understanding of novel approaches such as 
dendrimer based therapies, a brief description of the viral life cycle is required.  
The first step in the viral life cycle is attachment, fusion of the viral envelope and consequent 
entry into an immune cell. CD4 receptors bind the viral surface protein gp120, enabling 
further interaction with co-receptor proteins, predominantly CCR5 and CXCR4 [Eckert et 
al., 2001]. After CD4-virus binding, conformational changes in gp120 initiate fusion of the 
two membranes by reorientation of the transmembrane protein gp41. This step is a target for 
preventive therapy and drugs, and several HIV entry inhibitors are the subject of clinical 
trials. Among them, Enfuvirtide, Sifurvitide (blocks the surface envelope glycoprotein 41 of 
HIV-1, already approved) [Lalezari et al., 2003], Aplaviroc, Vicriviroc and Maraviroc are 
host co-receptor CCR5 antagonists [Liu et al., 1996; Dean et al., 1996], AMD11070 (CXCR4 
antagonist, in phase II clinical trials) [De Clercq, 2003; Hendrix et al. 2004] and other 
associated entry and fusion drugs are being developed and await approval [Esté & Telenti, 
2007].  
Viral reverse transcriptase copies the single-stranded RNA into double-stranded DNA. RT 
inhibitors are divided into two fundamentally different groups: nucleosides (NRTI) and 
non-nucleosides (NNRTI); AZV was approved six years after the discovery of HIV-1. The 
NTRIs represent nucleosides, mimic natural ones and are capable of competing with them. 
Activity, effectiveness and toxicity are highly dependent on the design of the NTRI. NNRTIS 
were developed to fight the virus selectively. Being approved, RTs reduce the viral load 
effectively, but toxicity, pharmacokinetics, drug clearance, dosing, cost and drug adherence 
are limiting factors, and multiple resistance remains the main obstacle [Basavapathruni & 
Anderson, 2007]. Delivering RTs using non-toxic vehicles can greatly improve the clinical 
effect.  
Once synthesized, the viral DNA is incorporated into a pre-integration complex to be 
transported to the nucleus. Viral proteins facilitate transportation and integration of the 
DNA chain into the host genome. At the late phase, mRNAs are produced and move out of 
nucleus to undergo translation and protein synthesis. After viral particle budding, viral 
DNA leaves the cell via exocytosis.  
The genome of HIV is encoded by single-stranded RNA [Turner & Summers, 1999].  
However, HAART prevents HIV-1 infected patients from making a complete recovery 
[Sekaly, 2008], and this therapy is associated with dangerous side-effects including 
mitochondrial toxicity and myopathy [Scruggs & Dirks Naylor, 2008], lipodystrophy 
[Mallewa et al., 2008] associated with insulin resistance and lipid abnormalities [Mallon, 
2007], and induced liver injury [Inductivo-Yu & Bonacini, 2008]. Therefore, new approaches 
to treating HIV-positive individuals are required that are  selective and impact only infected 
cells, or have no effects on healthy cells. Treatment systems that can cross the blood-brain 
barrier would be advantageous, and gene therapy [Strayer et al., 2008] or delivery using 
nanostructures could be realistic alternatives. 
3. Gene therapy: mechanism of RNA interference 
Gene therapy is a technique for replacing mutant genes in cells and tissues, and has been 
utilized for disorders such as Alzheimer's disease and Parkinson's syndrome [Kelly, 2007]. 
The ability to repair genes within a cell is a new potential approach for treatment of cells 
and tissues that possess abnormal gene patterns. Gene therapy is based on two conceptually 
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different approaches. The first, called up-regulation, suggests delivery of nucleic acids or 
corresponding constructs for expression of the gene of interest under the control of an 
appropriate promoter, resulting in increased target activity, i.e. in production of a protein 
playing the role of a drug. The other approach concerns the delivery of oligomeric genetic 
materials such as antisense oligodeoxynucleotides or siRNA (short interfering RNA) that 
cause a decrease in the target activity, resulting in inhibition of harmful mRNA expression 
and/or synthesis of harmful proteins. Referred to as down-regulation or gene silencing, this 
approach became key to the development of anti-cancer and anti-HIV vaccines.  
RNA interference (RNAi) was first used in plants as a tool for changing the color of petunias 
[Napoli et al. 1990; Sen & Blau, 2006]. RNAi as a gene silencing tool has wide therapeutic 
applications and can be utilized  in animal cells [Guo & Kemphues, 1995]. Three 
mechanisms can be applied within a cell, depending on the type of effector molecules: 
antisense single-stranded oligonucleotides (ODN), double-stranded antisense small 
interfering RNA (siRNA) and ribozymes. 
RNA interference is based on the ability of ODN, siRNA and ribozymes to stimulate specific 
degradation of an mRNA target with a sequence complementary to one or two strands of 
ODN, siRNA and ribozymes. When long double-stranded RNA enters a cell, it undergoes 
cleavage by endonucleases, resulting in short 19-21 bp double-stranded fragments with two 
protruding nucleotides at the 3’-ends of the strands. These short duplexes, called siRNA, 
form within a complex with protein catalytic structures causing directed degradation of 
complementary target mRNA. RNA interference is used to regulate gene expression and as 
a method for investigating functional genomics in eukaryotes. As for other nucleic acids, 
one of the main limitations of RNA interference for gene therapy concerns delivery of ODN 
or siRNA into cells.    
4. Barriers and vectors for delivering nucleic acids 
To explain the necessity for nucleic acid delivery systems, the barriers to nucleic acid 
delivery within organisms need to be discussed. Normally, introduction of free nucleic acid 
is accompanied by its enzymic degradation in the organism. Furthermore, RNAi effectors 
are unable to cross biological membranes readily owing to their strong negative charge, 
inducing poor cellular uptake. Therefore, delivery agents should maintain the biological 
activity of drugs and promote cell penetrating activities so that the process of RNAi is 
efficient; this necessitates the existence of vectors for nucleic acid packing and transport. 
Vectors aid nucleic acid delivery to zones necessary for its localization and provide efficient 
intracellular transport, predominantly to the nucleus. Viral vectors are efficient but 
shortcomings include high immunogenicity and carcinogenicity in vivo [Mulligan, 1993; 
Briand & Kahn, 1993]. Compared to viral systems, synthetic (non-viral) systems are 
characterized by lower efficiency but higher flexibility and safety [Eliyahu et al., 2005]. 
Normally, packing of nucleic acids is provided by electrostatic interaction of the anionic 
phosphate groups with positive charges on the synthetic vector, resulting in complex 
formation. 
Nucleic acid complexes with liposomes and various cationic linear polymers are the most 
widely used non-viral vectors. Complexes with liposomes are called lipoplexes, and those 
with linear polymers are called polyplexes. However, the development of nanotechnology 
led to the appearance of new nanocomposites for gene delivery – dendrimers [Eliyahu et al., 
2005]. 
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5. Dendrimers as new class of nanoparticles for drug and gene delivery 
The application of nanotechnology in biology and medicine induced the appearance of new 
devices, supramolecular systems, structures, complexes and composites. Dendrimers (from 
the Greek “dendron” – tree and “meros” – branch) are excellent examples of 
nanotechnological composites [Newkome et al., 1986; Tomalia, 1995; Fischer & Vogtle, 1999]. 
They are globular in shape, with a topological structure formed by monomeric subunit 
branches diverging to the sides from the central nucleus (Fig. 1). Properties of synthesized 
macromolecules can be precisely assigned in advance by choosing appropriate monomers 
and functional groups [Newkome et al., 1986; Tomalia, 1995; Fischer & Vogtle, 1999; Bosman 
et al., 1999]. The following features can be distinguished in dendrimers: (i) multivalent 
surface containing numerous potentially active sites; (ii) envelopes surrounding the nucleus; 
(iii) the nucleus with attached dendrons. 
 
 
Fig. 1. Dendrimer structure. 1) Nucleus, 2) Internal cavities, 3) Surface groups. 
Two main strategies have been used during dendrimer synthesis: a divergent method, in 
which dendron growth begins from the nucleus, and a convergent method in which already 
finished dendrimer branches join the nucleus. According to the divergent method proposed 
by the Tomalia and Vogtle groups [Tomalia, 1995; Fischer & Vogtle, 1999], dendrimer 
synthesis includes association of monomeric modules in a radial structure, from one branch 
to another, following definite rules. In particular, the dendrimer increases in size from one 
layer to another (from one generation to the next). According to the convergent method 
proposed by Hawker and Frechet [Hawker & Frechet, 1990], branches join the nucleus at the 
final stage of the process and form the dendrimer, and are grown first in the course of 
dendrimer synthesis. 
An interesting property of dendrimers is the dependence of their solution viscosity on 
molecular mass, which differs from that for linear polymers [Frechet, 1994]. Solution 
viscosity for linear polymers is described by the exponential function η ~ CN, where C is 
polymer concentration and N is the exponential parameter (1 < N <10), but the viscosity of 
dendrimer solutions is described by the linear function η = η0(1 + kφ), where k is a constant 
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and φ is the disperse phase volume fraction. Therefore, on increasing dendrimer generation 
(molecular mass), at a certain point the viscosity in solution begins to decrease. This effect is 
the result of globular dimensions of high dendrimer generations [Matthews et al., 1998]. 
With regard to modifications, over 100 types of dendrimers have been synthesized, although 
there are five common families. 
Polyamide amine (PAMAM) dendrimers [Tomalia, 1995] are based on the ethylenediamine 
nucleus, and their branches are designed from methyl acrylate and ethylenediamine. Half 
generations of PAMAM dendrimers have surface carboxyls, while complete generations 
have surface amino groups. At present, there is an abundant choice of PAMAM dendrimers 
with various types of surface groups. Polypropyleneimine (PPI) dendrimers [Matthews et 
al., 1998] are based on the butylenediamine nucleus and polypropyleneimine monomers. 
Besides PPI, another popular abbreviation of these dendrimers is DAB (diaminobutyl), 
based on the name of the nucleus, and these are commercially available. Phosphorus 
dendrimers were synthesized by the Majoral and Caminade group [Majoral et al., 2002]. 
Phosphorus atoms are present in the nucleus and branches of these dendrimers. Carbosilane 
dendrimers are based on a silicon nucleus and have ammonium or amino groups at the 
periphery [Ortega et al., 2006]. Polylysine dendrimers are based on the amino acid lysine 
and have polylysine branches and surface groups [Vlasov, 2006], and these are 
commercially available. 
The architecture and properties of dendrimers depends on the generation. Low generations 
of dendrimers have an open, flattened and asymmetric shape, but as the generation 
increases the structure becomes globular and densely packed at the periphery. Inside 
dendrimers there are empty cavities where small therapeutic molecules can be entrapped 
and safely transported to targets. Another important feature of dendrimers is 
monodispersity. The classical polymerization process is usually random and produces 
molecules of different sizes, whereas the size and molecular mass of dendrimers can be 
specifically controlled during synthesis.  
Dendrimers possess many functional end groups, which are responsible for high solubility 
and reactivity. Long chain molecules with many reaction sites interact with dendrimers by 
wrapping around them, as normally happens for single- or double-stranded nucleic acids. 
These properties make dendrimers suitable for targeting, microarray systems, and catalysis 
and drug delivery systems [Matthews et al., 1998]. 
6. Dendrimers themselves as anti-HIV therapeutic agents 
Dendrimers are anti-HIV therapeutic agents. PAMAM polyanionic phenyldicarboxylic acid 
(BRI6195) and naphthyldisulfonic acid (BRI2923) terminated dendrimers were synthesized 
as inhibitors of the viral replication cycle in different strains of HIV-1 and in various cell 
lines including those that display reverse transcription resistance. Suppression provided by 
such macromolecules is based on the interaction with the envelope protein gp120, which 
prevents the first steps of cell infection, i.e. binding to host-cells. Owing to the different cell 
penetration rates of BRI6195 and BRI2923 compounds, the latter was demonstrated to 
exhibit another antiviral activity during reverse transcription and integration steps. 
Unfortunately, it has been found that some gp120 mutations display inconsistency, 
preventing the described PAMAM dendrimers from completely and successfully curing 
patients after treating cells [Witvrouw, 2000].  
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A new class of polycationic molecules called “VIOLOGEN” was synthesized and 
investigated by Asaftei and De Clercq as candidate antiviral drugs [Asaftei & De Clercq, 
2010]. They represented dendrimers with bipyridiniumhexafluorophosphate end groups 
consisting of viologen units, synthesized with a phenyl- or benzyl-type core, carrying 
between one and 90 charges per molecule. Inhibition of HIV-1 replication of some 
constituents in MT-4 cells were demonstrated at EC50=0.26±0.08 μM, SI=75.7. Investigation 
of the activity of compounds on peripheral blood mononuclear cells (PBMC) demonstrated 
their inability to interfere with the viral life cycle, showing that the mechanism of HIV-1 
inhibition concerned dendrimers and heparin sulfate interaction. Therefore, it was 
concluded that viologen compounds block the electrostatic interaction of cell surfaces and 
viral particles. Polycationic dendrimers were tested in two steric architectures: spheroidal 
and comb-branched. This demonstrated that spherical branched organization is an 
advanced property of dendrimeric molecules. Spherical forms of “VIOLOGEN” bound to 
the viral envelope better than comb-branched dendrimers, indicating increased efficacy 
against the virus. Moreover, the intensity of viral activity correlated with surface charges, 
i.e. a lack of charges reduced attempts to stop HIV-1 replication in cells [Asaftei & De 
Clercq, 2010].  
The scientific group led by Prof. Majoral [Pérez-Anes et al., 2010] is developing multivalent 
catanionic galactosylceramide (GalCer) dendritic analogs with antiviral activity (inhibition 
of HIV-1 entry into the host-cell), based on treating epithelial cells with a lack of CD4 
receptors. The HIV virus targets immune cells via a specific interaction between gp120 and 
the amino-terminal immunoglobulin domain of CD4 [Ho et al., 1995]. Therefore, it was 
supposed that the presence of this receptor was the determining factor for cells to absorb 
small viral particles. However, the human immunodeficiency type 1 virus was subsequently 
found to bind to CD4 (-) cells. Widely expressed at cell surfaces, glycosphingolipid GalCer 
plays the role of an alternative receptor for gp120 [Yahi et al., 1994], explaining why success 
of infection depends on GalCer/gp120 interaction in cells with a blocked or absent CD4 (+)-
mediated pathway. The first attempt to use this concept was in 2000, when multivalent 
polysulfated PPI glycodendrimers were tested as binding antagonists of the virus. Results 
indicated similar inhibitory and cytotoxicity properties as dextran sulfate [Kensinger et al., 
2004]. More recent in vitro studies have demonstrated that HIV-1 inhibitory properties of 
compounds, based on phosphonic acid terminated dendrimers and N-hexadecylamino 
lactitol moieties, make them promising anti-HIV drug candidates. However, their low 
therapeutic indices in cellular studies required scientists to modify the stability of 
assemblies in vitro.  
Another attempt to uncover novel antiviral dendrimers resulted in scientists using the 
disaccharide cellobiose as a terminal layer of polylysine dendrimers generation 3. Further 
sulfation of the terminating groups allowed them to interact with the viral surface 
electrostatically, particularly with the positively charged envelope glycoprotein gp120. 
Polylysine dendrimers exhibited antiviral activity as high as that of approved drugs, 
maintaining low level cytotoxicity and revealing additional anticoagulant properties. Very 
low level anti-HIV-1 activity and anticoagulant activities responsible for uncontrolled 
bleeding are substantial shortcomings of this method [Han et al., 2010].  
The so-called “Trojan horse”, in vitro studies of HIV treatments with low cytotoxicity, is the 
new concept in HIV research. Such an approach has demonstrated that a polylysine 
dendrimer-based container is the optimal choice for initiating cytotoxic mechanisms 
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comprising proteins penetrating cells to inhibit the chymotrypsin-like activity of 
proteasomes. The “Trojan horse” includes small cytotoxic molecules as functioning agents 
conjugated with a “steric cap”, and a relatively big carrier to avoid immediate entry into the 
catalytic hollow of proteasomes. The effect is thought to be activated by viral proteases via 
cleavage of the linkage between the agent and nanoparticle, although further investigations 
are required to validate this type of approach [Buckley et al., 2011]. 
At present there is only one product based on dendrimers on the market. The product, 
VivaGel®, is produced by Starpharma and protects again sexually transmitted diseases and 
human immunodeficiency virus (HIV). It is a vaginal microbicide gel under development 
for the prevention of sexually transmitted infections (STIs) including genital herpes and HIV 
infection. The VivaGel® product concept is designed to offer a safe, convenient and 
affordable means for women to protect themselves from infection with genital herpes and 
HIV during sex. Surveys demonstrate that there is substantial demand in North America 
and Europe for such a product, with an estimated billion dollar market for STI prevention 
products in the developed world. 
7. Potential revolution in gene delivery: dendrimers as gene carriers in anti-
HIV therapy 
No dendrimer-based delivery systems are approved or the subject of clinical trials for HIV-1 
treatment as an application of gene therapy. Nevertheless, numerous studies are currently 
underway to develop vectors based on dendrimeric polymers for improved delivery of 
approved drugs and nucleic acids, as this is a promising approach that can potentially 
overcome all known safety issues. There are several reviews concerning the application of 
nanotechnology [Neves et al., 2010; Mallipeddi & Rohan, 2010; Sharma & Garg, 2010], but 
none provides total and complete descriptions of associated problems. This sub-section has, 
as far as possible, attempted to summarize all attempts to elaborate effective nucleic acid 
carriers by applying various types of dendrimers, generations and with different 
modifications.  
HAART antiviral therapy has critical side effects and does not provide complete recovery 
from infection. Furthermore, some medical components often included in drug cocktails for 
antiviral chemotherapy (for example NRTIs) cause intensified neuropathological disorders 
[Cherry et al., 2003] that can lead to nervous system degradation. Targeting familiar drug 
molecules directly to infected cells would improve their safety.  
Dendrimer-based carriers were developed to support, rationalize and improve drug 
efficiency, avoiding consequences observed for pure drugs that were administered without 
special carriers. Polymolecular compounds were proposed as a delivery system. Nanogel 
particles consisting of PEG- (polyethylene glycol) and Pluronic-PEI- (polyethylenimine) 
biodegradable networks, i.e. star PEG-g-PEI and PAMAM-PEI-g-PEG, were synthesized and 
investigated in terms of drug delivery analysis. Recent studies have shown that the 
phosphorylate-modified nucleoside analogs zidovudine (AZT) and didanosine (ddI) 
coupled with nanogels were effective in terms of cellular uptake and had increased and 
upgraded target selectivity. Moreover, the process of mtDNA depletion, responsible for 
neuropathy reinforcing, was reduced threefold by administering NRTIs with nanocarriers 
rather than using a pure NRTI injection [Vinogradov et al., 2010]. Such vectors were 
demonstrated to be a promising tool for reaching viral reservoirs in the central nervous 
system (CNS) and were capable of crossing the blood-brain barrier [McGee et al., 2006]. 
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When cells infected with HIV-1 can be killed in a targeted manner, mature non-proliferating 
active macrophages in the organism can reproduce viral particles, and this is one reason for 
the failure of existing therapies. Development of non-toxic targeting nanocarriers could be 
vital in overcoming this problem. 
Modified PPI dendrimers have been used for the aim of targeted delivery into cells involved 
in highly conserved retention, and mannosylated PPI dendrimers possess double the effect 
in terms of viral attack, improving biological properties of drugs and displaying antiviral 
activity themselves owing to specific binding and their penetrating ability via cell receptors 
[Dutta  & Jain, 2007]. As demonstrated for complexes of coupled tuftsin and zidovudine, 
antiretroviral activity of each separate compound was not enough for them to be considered 
anti-HIV agents in isolation, but when conjugated they represent a good method and are 
likely to enter phase I clinical trials [Fridkin et al., 2005]. Modifying dendrimers with tuftsin 
revealed them as the most biocompatible carriers, demonstrating striking results in studies 
concerning infected macrophages [Dutta et al., 2007]. Tuftsin is a tetrapeptide (Thr-Lys-Pro-
Arg) related to macrophage activation, and it binds specifically to macrophages, monocytes 
and polymorphonuclear leukocytes. Its covalent conjugation with 5 generation PPI 
dendrimers increases entrapment (49.3%) of Efavirenz into the internal cavities of the 
transmitting agent, compared with 37.5% entrapment efficiency for unmodified dendrimers. 
Such vehicles significantly prolong release of the non-nucleoside reverse transcriptase 
inhibitor Efavirenz through controlled drug administration. This delivery system also 
provides 34-fold increased cellular uptake and more than 7-fold augmented anti-HIV 
activity compared with pure drugs without carriers [Dutta et al., 2008].  
PPI dendrimers are characterized as good binding agents for antisense 
oligodeoxynucleotides, resulting in compact complexes with close to neutral charge. Amino-
terminated dendrimers of second, third and fourth generations can produce dendriplexes 
suitable for cell transfection and to release cargos in a time-dependent manner [Pedziwiatr-
Werbicka et al., 2011]. Only first stage results have been published so far, but this should not 
minimize the importance and potential of such an approach.  
The most studied PAMAM dendrimers have the potential to inhibit viral replication by 
blocking interaction of the Tat peptide and transacting responsive element (TAR) RNA. This 
process is essential for the production of full-length viral transcripts and proliferation of the 
virus. Establishment of new drugs that disrupt this binding within cells is a new concept for 
anti-HIV-1 therapeutics. [Zhao et al., 2004]. 
Carbosilane dendrimers containing ammonium or amine groups at their periphery are 
nanocarriers that are appropriate vectors for successful gene therapy against HIV-1. They 
are water-soluble and polycationic, and effectively bind small nucleic acid chains. After 
complete dendriplex formation, antiviral oligodeoxynucleotides (ODN) were immune to the 
actions of their binding proteins [Shcharbin et al., 2007;  Chonco et al., 2007], and the 
inhibitory effect of viral replication in cells in the presence of human plasma was increased 
by 25-30%, similar to that for naked ODNs. In order to conserve the biological ability of 
siRNA to have a role in the RNA interference process inside infected lymphocytes, second 
generation amino-terminated carbosilane dendrimers (2G-NN8 and 2G-NN16) were tested, 
resulting in  formation of strong complexes with siRNAs (siP24, siNEF and siGAG1 
[Shcharbin  et al., 2011]. These are antisense to HIV regions responsible for p24, nef and gag 
protein expression, respectively,  with diameters between 300 and 370nm, protection against 
RNase digestion, low cytotoxicity at therapeutic concentrations (sufficient to 40% HIV 
www.intechopen.com
 
Dendrimers in Anti-HIV Therapy 
 
369 
inhibition), and comparatively good ability to inhibit viral replication in peripheral blood 
mononuclear cells and human leukemia T lymphocytes. Gradual hydrolysis of the interior 
carbon-silicon bonds leads to time delayed cargo liberation (4-24 hours), which would be 
important for treatment as the necessary amounts of siRNA and ODNs would be decreased 
and the effect is believed to be longer [Weber et al., 2008]. 2G-NN16 dendrimers coupled 
with antiviral siRNA have been demonstrated to cross the blood-brain barrier (BBB) in an in 
vitro model, making the possibility of conducting gene therapy using dendrimer-based 
delivery in human astrocytes and to fight viruses within CNS cells a more realistic option. 
Transfection with infected and non-infected human astrocytoma cells did not result in 
significant cytotoxicity when treated with up to 24µM/ml dendriplexes, while sequence-
specific down-regulation of the housekeeping gene GAPDH was observed, indicating the 
ability of siRNA to exert its biological function. At the same time, inhibition of X4-HIV NL4-
3 and R5-HIV strains of HIV-1 by dendriplexes was 80% as effective as treating cells with 
naked siRNA. In spite of numerous positive results for carbosilane dendrimers as a delivery 
system in in vitro studies, this approach is still at the pre-clinical experimental stage. 
Theoretically, dendriplexes did not have sufficiently small-scale diameters to penetrate 
deeply into brain issues, but in practice transcytosis though the blood-brain barrier was 
demonstrated. Furthermore, structural and functional alterations of BBB occur during HIV 
infection [Jiménez et al., 2010]. Injection of pure dendrimers causes a high rate of cell death 
due to electrostatic interactions of polycationic surface groups and negatively charged cell 
membranes, although this has no effect on pivotal properties of dendritic cells (mature and 
immature) in terms of linking adaptive and innate immunities [Pion et al., 2010]. 
8. Conclusion 
Dendrimers are nanomaterials with great potential to be anti-HIV therapies of the future. 
However, despite potential applications, at present there is only one product based on 
dendrimers available on the market. This product, VivaGel® (Starpharma, Australia), 
protects against sexually transmitted diseases and human immunodeficiency virus. 
Systematic studies concerning dendrimers are required for the development of new 
dendrimer-based antiretroviral drugs.  
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